UBS upgraded shares of Chemours Co CC following better-than-expected second-quarter results, helped by cost cutting and fluoroproducts growth. Analysts John Roberts and Edlain Rodriguez said their prior concerns regarding Chemours' ability to deliver cost savings, fluoroproducts growth and liabilities have been disproved by the thumping performance. SourceStochastics are in neutral territory so the shares will likely continue their movement inside the rising channel. $CC, Chemours Company (The) / H1